Myasthenia Gravis
Myasthenia Gravis
Learning Outcomes
- Define myasthenia gravis.
- Explain the pathophysiology and types of myasthenia gravis.
- State the clinical manifestations and complications.
- State the diagnostic investigations.
- Explain the management, including nursing care using the nursing process.
Introduction
- Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder.
- Characterized by fluctuating weakness of voluntary muscle groups.
Definition
- MG is an autoimmune disorder where antibodies destroy communication between nerves and muscles.
- Results in weakness of skeletal muscles, especially those controlling eyes, mouth, throat, and limbs.
- Antibodies attack acetylcholine (ACh) receptors.
Pathophysiology
- Normally, nerve impulses release acetylcholine (ACh) at the neuromuscular junction.
- ACh binds to ACh receptors, leading to muscle contraction.
- In MG, antibodies block, alter, or destroy nicotinic ACh receptors.
- This prevents ACh from binding, resulting in no contraction.
Neuromuscular Junction
- Acts as a bridge between the nervous and muscular systems.
- Changes can impair skeletal muscle contractions.
Etiology
- Receptors at the muscle surface are destroyed or deformed by antibodies.
- Causative factor is unknown, but may have a genetic link.
- Autoantibodies destroy acetylcholine receptors.
- Thymus tumors are found in 15% of patients.
Pathophysiology and Myasthenic Crisis
- Bulbar weakness leads to altered cough and swallowing reflexes.
- Ventilatory muscle weakness reduces tidal volume and functional residual capacity.
- Accumulation of secretions leads to oropharyngeal "lake."
- This can result in atelectasis, microaspirations, increased upper airways resistance, and work of breathing.
- Hypoventilation causes dead space, V/Q alterations, hypoxemia-hypercapnia, and respiratory failure.
Types of Myasthenia Gravis
- Congenital MG: Genetic defect, not autoimmune, autosomal recessive.
- Transient Neonatal MG: Mother’s antibodies transmit through placenta.
- Juvenile MG: Develops in childhood/adolescence, 10% of cases, usually in girls.
- Generalized MG: Most common, women (20-30yrs), men (50-60yrs).
- Ocular MG: 10-15% cases, affects ocular muscles only.
Clinical Manifestations
- Ocular and Facial: Ptosis, diplopia, facial weakness, dysphagia, dysarthria.
- Musculoskeletal: Weakness and fatigue in hands, arms, legs, and neck muscles.
- Respiratory: Weakening of intercostal muscles, decreased diaphragm movement, breathlessness, dyspnea, poor gas exchange.
- Nutritional: Inability to chew and swallow, decreased ability to move tongue, impaired fine motor movements.
Diagnosis
- History and physical examination.
- Blood analysis: Elevated levels of acetylcholine receptor antibodies, Anti-MuSK antibodies.
- Tensilon test (Edrophonium test).
- Interleukin 2-receptors: Elevated in general and bulbar MG.
- Single-fiber electromyography (EMG): Detects impaired nerve-to-muscle transmission.
- Imaging scans (CT or MRI): Shows thymus enlargement.
- Repetitive nerve stimulation test: Muscle weakness.
- Ice test: Positive if ≥2-mm rise in eyelid occurs after ice removal.
Tensilon Test
- Edrophonium (Tensilon) is administered IV (2 mg at a time to a total of 10 mg).
- Observe for improvement in muscle strength 30 seconds after injection.
- Increased muscle strength indicates likely myasthenia gravis.
- IV atropine should be available for allergic reactions.
Pharmacological Management
- Immunosuppressive Therapy: Prednisone, Azathioprine.
- Acetylcholinesterase Inhibitors: First-line therapy, e.g., Neostigmine bromide (Pyridostigmine), Edrophonium chloride (Tensilon).
- Immunoglobulin Therapy
- Corticosteroids: Suppress the immune system, decreasing autoantibody production.
- Plasmapheresis: Separates plasma from blood, discards it, and returns RBCs and electrolytes to the client.
Management
- Symptomatic: Anticholinesterase drugs (Pyridostigmine, Neostigmine) ensure healthy ACh supply in synaptic gap.
- Short Term: Plasmapheresis, IVIG to remove or neutralize circulating antibodies.
- Long Term: Glucocorticoids (Prednisolone) to limit antibody production, Immunosuppressants (Cyclosporine, Methotrexate, Azathioprine) to prevent antibody production.
- Surgery: Thymectomy for patients < 60 years.
Complications
- Myasthenic Crisis: Sudden exacerbation of motor weakness, risk of respiratory failure and aspiration, often due to undermedication or infection.
- Manifestations include tachycardia, tachypnea, severe respiratory distress, dysphagia, restlessness, impaired speech, and anxiety.
- Tensilon test: Positive. Emergency: Ventilator assistance needed!
- Cholinergic Crisis: Overdosage of anticholinesterase medication, leading to severe muscle weakness, vertigo, and respiratory distress.
- GI manifestations. Tensilon test: Negative. Emergency: Ventilator assistance needed!
Nursing Diagnosis
- Ineffective breathing pattern related to intercostal muscle weakness.
- Ineffective airway clearance related to muscle weakness.
- Impaired verbal communication related to weakening of the larynx.
- Disturbed sensory perception related to ptosis.
Patient Teaching
- Educate patient/family about disease process, complications, and treatments.
- Teach about medications, uses, dosage, etc.
- Caution about medications that exacerbate muscle weakness (e.g., beta blockers, calcium channel blockers, quinine, quinidine).
Summary
- MG is a chronic autoimmune neuromuscular disorder causing skeletal muscle weakness.
- Autoantibodies attack ACh receptors at the neuromuscular junction, impairing nerve signal transmission.
- Leads to muscle weakness, ptosis, diplopia, and potential respiratory distress.
- Complications include myasthenic and cholinergic crises.
- Diagnosis via Tensilon test, serological testing, and EMG.
- Management includes anticholinesterase medications, immunosuppressants, plasmapheresis, IVIG, thymectomy, and supportive care.
- Nursing care focuses on monitoring respiratory function, ensuring proper nutrition, administering medications, encouraging rest, and providing patient education.
Parkinson's Disease
Learning Outcomes
- Define Parkinson's disease (PD).
- Explain the pathophysiology and types of PD.
- State the clinical manifestations and complications of PD.
- State the diagnostic investigations for PD.
- Explain the management, including nursing care, using the nursing process.
Introduction
- Parkinson's disease is a progressive nervous system disorder affecting movement.
- Symptoms start gradually, often with a tremor in one hand, stiffness, or slowed movement.
Parkinson’s Disease (PD) Definition
- Chronic, progressive neurodegenerative disorder.
- Characterized by bradykinesia, rigidity, tremor at rest, and gait changes.
Functions of Basal Ganglia
- Plays an important role in planning and programming movement.
- Inhibits specific motor synergies.
- Important in cognitive processes and awareness of body orientation in space.
- Ability to adapt behavior as task requirements change, and motivation.
Parkinson's Disease Mechanisms
- Degeneration of dopaminergic neurons that produce dopamine.
- Loss of melanin-containing neurons causing depigmentation.
- Impaired extrapyramidal tract controlling motor function.
- Formation of Lewy bodies.
- Loss of dopamine disrupts balance between dopamine (DA) and acetylcholine (ACh) in the basal ganglia.
- Degeneration of the dopamine-producing neurons in the substantia nigra of the midbrain.
Etiology
- Exact cause is unknown.
- Potential factors include heredity, family history, advancing age (above 60), male sex, low estrogen levels, medications (metoclopramide, reserpine), agricultural work (exposure to toxins), and head injury.
Clinical Manifestations
- Rigidity: Increased resistance to passive motion, cogwheel rigidity (jerky, ratchet-like resistance).
- Tremor: Involuntary oscillation of body part, resting tremor, pill-rolling tremor of the hand.
- Akinesia: Absence of movement; freezing may occur, hypokinesia (reduced amplitude of movement).
- Postural Instability: Patients may be unable to stop themselves from going forward (propulsion) or backward (retropulsion).
- Hypomimia: Masked facial expression.
- Other Symptoms: Drooling, low volume speech, dysarthria, problem with swallowing, stiff face, altered cognitive function (dementia).
Complications
- Motor symptoms (dyskinesia), dementia, depression, hallucinations, psychosis, dysphagia, malnutrition, aspiration pneumonia, orthostatic hypotension, and risk for falls.
Diagnosis
- Based on clinical features.
- CT scan or MRI of head to rule out secondary causes.
- PET scan to evaluate levodopa uptake and conversion to dopamine in the corpus striatum.
Anti-Parkinsonism Medications
- Levodopa (L-Dopa): Most effective agent for controlling symptoms.
- Sinemet (Levodopa/Carbidopa): Levodopa converts to dopamine in the brain, carbidopa increases effectiveness and prevents side effects.
- Dopamine Receptor Agonists: Activate or stimulate dopamine receptors (e.g., bromocriptine, ropinirole, pramipexole).
- Monoamine Oxidase Inhibitors: Block the breakdown of dopamine (e.g., selegiline, rasagiline).
Surgical Management
- Surgery is optional, when medication doesn't relieve the symptoms.
- Thalamotomy: An opening is made to the thalamus to improve brain function.
- Deep Brain Stimulation: Pulse generator sends high-frequency electrical impulses to the thalamus to control tremors.
- Electrodes are surgically placed in the brain and connected to a neurostimulator (pacemaker device) in the chest.
Physiotherapy
- Combined approach of physical therapy and pharmacological intervention.
- Physical therapist should be aware of the medications the patient is taking and its potential adverse effects.
- Includes exercise, strength, and balance training, verbal skills practice with breath control.
Nursing Management
Nursing Assessment: Assess symptoms, their effect on functioning, mobility, feeding, communication, and self-care difficulties. Assess cranial nerves, cerebellar function, motor function, gait, speech, and signs of depression. Assess family support and access to social services.
Nursing Diagnosis:
- Impaired physical mobility related to bradykinesia, rigidity, and tremors.
- Imbalanced nutrition less than body requirements related to motor difficulties.
- Impaired verbal communication related to decreased speech volume.
- Constipation related to diminished motor function and inactivity.
- Ineffective coping related to physical limitations and loss of independence.
- Risk for falls.
- Impaired sleep pattern.
Multiple Sclerosis
Learning Outcomes
- Understand the physiology of multiple sclerosis.
- Describe the pathophysiology of multiple sclerosis.
- Understand the signs and symptoms of multiple sclerosis.
- Illustrate the investigations and management of multiple sclerosis.
- Understand nursing management of multiple sclerosis.
Introduction
- Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, including the brain and spinal cord.
- Myelin is produced by oligodendrocytes, which support neurons.
- In MS, the immune system attacks and destroys myelin, disrupting communication between neurons, leading to sensory, motor, and cognitive problems.
What is MS?
- Multiple sclerosis (MS) OR Disseminated sclerosis.
- Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged.
- This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms.
Facts About MS
- MS was first described in 1868 by Jean-Martin Charcot.
- The name multiple sclerosis refers to the numerous scars (sclerae—better known as plaques or lesions) that develop on the white matter of the brain and spinal cord.
Etiology
- Idiopathic.
- Genetic factor: Female.
- Environmental factor:
- Infections such as measles, mumps, rubella, Epstein–Barr virus.
- Vitamin D deficiency
Pathogenesis of MS
- Myelin protective sheath, axon, oligodendrocyte
- Blood-Brain Barrier:
- Allows some specific molecules to get entry such as T-cells or B-Cells
- T-cells cross the BBB and attached to specific type of protein present in myelin
- T-cell Activated by myelin and changes to endothelial cells to express more receptors
- It allow immune cells to easily bind to receptors
- These myelin-specific T-cells produce cytokines (IL-1,IL-2, INF-GAMMA) Which dilate blood vessels
- Cytokines attract Macrophages & B-Cells as a part of inflammatory reaction
- B-Cells Produce antibodies, which mark to myelin proteins
- Macrophages targets the Antibodies markers and engulf the Oligodendrocytes
- In process of remyelination these Regulatory T-cells suppress the immune cells
Types of MS
Pathophysiology:
- 2 stages:
- 1st stage: development of small inflammatory lesions
- 2nd stage: lesions extend consolidate as gliosis and demyelination occurs
- 2 stages:
4 possible patterns:
- Relapsing-remitting: periodic remission and exacerbation of manifestations
- Primary progressive: almost continuous neurologic deterioration from onset of manifestation
- Secondary progressive: gradual deterioration with or without relapses
- Progressive relapsing: gradual progression of neurologic deterioration with superimposed relapses
- Relapsing-remitting: periodic remission and exacerbation of manifestations
Clinical Manifestations
Charcot's neurologic triad of multiple sclerosis
- Dysarthria.
- Nystagmus.
- Intention Tremor.
Others clinical manifestation
- Dysphagia
- Loss of vision (optic neuritis)
- Blurring of the vision
Cont…
- Muscles weakness & spasm
Ataxia (Loss of balance or coordination)
* Paresthesias(Tingling,itching)LHERMITTE’S SIGN
- (Electric shocks runs down back & radiate to limbs when bending neck forward)
Clinical manifestations: Myelopathic manifestations Source:
Diagnostic Measures
- HISTORY(infection, Genetic factors Neurological Examination
- CT OR MRI CSF EXAMINATION Visual evoked potential
Nursing diagnosis
- Ineffective Airway clearance related to lung infection and thick mucus
- Activity intolerance related to fatigue and spasticity
- Self care deficit: toileting, feeding and grooming related to muscle weakness
- Impaired physical mobility related to muscle weakness
- Impaired urinary elimination related to bladder dysfunction
- Deficient knowledge related to condition and home care
Management of MS
Purposes:
- to treat manifestations, modify course of disease or interrupt progression of disease
Drug groups:
* Immunomodulators i.e., Interferon beta-1a (Avonex)
* Adrenocorticosteroids i.e., Methylprednisolone (Medrol), Prednisolone, ACTH
* Muscle relaxants i.e., Baclofen (Lioresal), Diazepam (Valium)
* Immunosuppressants i.e., Azathioprine (Imuran), Cyclophosphamide (Cytoxan)Non-pharmacological management
- Physical therapy
- Cognitive Rehabilitation therapy
Surgical Management
- Deep brain stimulation: a surgeon places an electrode in thalamus. The electrodes are connected to a pacemaker-like device by wires. “brain pacemaker,” deep brain stimulation works by blocking errant signals from damaged brain cells to “reset” the brain’s natural rhythm. This can help decrease or stop tremors entirely.
Treatment Considerations - Medications
- Intrathecal baclofen pump therapy a Surgeon will implant a pump near the spinal cord. This pump is programmed to deliver the medication on a regular basis. For most people, the surgery is easily managed. Some people may experience soreness around the incision site. The pump will need to be refilled every few months
Summary
- MULTIPLE SCLEROSIS is a Chronic & progressive Autoimmune disorder and the most common pattern is the relapsing-remitting type and slightly worsening their over all condition.
- T-cells cause inflammation and damage to oligodendrocytes in the CNS which leaves behind scarred areas of demyelinated neurons called plaques which cause variety of symptoms depending on the location.